- Home
- TSBK vs MNPR Comparison
TSBK vs MNPR Comparison
Compare TSBK & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSBK
- MNPR
- Stock Information
- Founded
- TSBK 1915
- MNPR 2014
- Country
- TSBK United States
- MNPR United States
- Employees
- TSBK N/A
- MNPR N/A
- Industry
- TSBK Banks
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- TSBK Finance
- MNPR Health Care
- Exchange
- TSBK Nasdaq
- MNPR Nasdaq
- Market Cap
- TSBK 242.0M
- MNPR 250.0M
- IPO Year
- TSBK 1998
- MNPR 2019
- Fundamental
- Price
- TSBK $30.80
- MNPR $40.25
- Analyst Decision
- TSBK
- MNPR Strong Buy
- Analyst Count
- TSBK 0
- MNPR 4
- Target Price
- TSBK N/A
- MNPR $43.00
- AVG Volume (30 Days)
- TSBK 9.0K
- MNPR 71.2K
- Earning Date
- TSBK 01-27-2025
- MNPR 03-27-2025
- Dividend Yield
- TSBK 3.25%
- MNPR N/A
- EPS Growth
- TSBK N/A
- MNPR N/A
- EPS
- TSBK 3.10
- MNPR N/A
- Revenue
- TSBK $75,328,000.00
- MNPR N/A
- Revenue This Year
- TSBK N/A
- MNPR N/A
- Revenue Next Year
- TSBK N/A
- MNPR N/A
- P/E Ratio
- TSBK $9.94
- MNPR N/A
- Revenue Growth
- TSBK N/A
- MNPR N/A
- 52 Week Low
- TSBK $23.93
- MNPR $1.72
- 52 Week High
- TSBK $33.98
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- TSBK 54.87
- MNPR 49.34
- Support Level
- TSBK $29.97
- MNPR $38.80
- Resistance Level
- TSBK $30.69
- MNPR $45.60
- Average True Range (ATR)
- TSBK 0.62
- MNPR 5.19
- MACD
- TSBK 0.03
- MNPR -1.50
- Stochastic Oscillator
- TSBK 63.88
- MNPR 9.37
About TSBK Timberland Bancorp Inc.
Timberland Bancorp Inc is a bank holding company. The bank offers a variety of services such as checking accounts, online and mobile banking, savings accounts, home loans, consumer loans, construction loans, business rewards, cash management, small business solutions, and business checking accounts among others. Company also offers loans to real estate, including residential and commercial / multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans and land loans. The company mainly operates in the United States.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.